Bacteriological and clinical evaluations of cefmenoxime in neonates and premature infants

K. Sunakawa, Y. Ishizuka, H. Akita, S. Iwata, Y. Sato

Research output: Contribution to journalArticle

Abstract

The antimicrobial activity of cefmenoxime (CMX) against B group Streptococcus was investigated. The clinical efficacy of CMX was determined in neonates and premature infants. The results are summarized below. 1. MIC's of CMX against 39 strains of B group Streptococcus obtained from the pregnant vagina were below 0.05 μg/ml. 2. CMX was given in dose of 20 mg/kg by intravenous bolus injection to 3 neonates with birth weight over 2,500 grams. Peak serum concentrations ranged from 54.0 to 199 μg/ml and the mean half/life was 1.8 hours. 3. Efficacies of CMX were good to excellent in 5 cases administered for treatment and in 4 cases for prophylaxis. As abnormal laboratory parameteres, elevation of GOT and eosinophilia were observed in each 2 cases. 4. Examinations on intestinal bacteria in 2 cases revealed that CMX gave as much influences to the flora as other third-generation cephems. 5. The vitamin K defficiency were observed in 2 out of 6 cases examined.

Original languageEnglish
Pages (from-to)2617-2626
Number of pages10
JournalJapanese Journal of Antibiotics
Volume42
Issue number12
Publication statusPublished - 1989

Fingerprint

Cefmenoxime
Premature Infants
Newborn Infant
Streptococcus agalactiae
Vitamin K
Eosinophilia
Vagina
Birth Weight
Intravenous Injections
Half-Life
Bacteria
Serum

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Sunakawa, K., Ishizuka, Y., Akita, H., Iwata, S., & Sato, Y. (1989). Bacteriological and clinical evaluations of cefmenoxime in neonates and premature infants. Japanese Journal of Antibiotics, 42(12), 2617-2626.

Bacteriological and clinical evaluations of cefmenoxime in neonates and premature infants. / Sunakawa, K.; Ishizuka, Y.; Akita, H.; Iwata, S.; Sato, Y.

In: Japanese Journal of Antibiotics, Vol. 42, No. 12, 1989, p. 2617-2626.

Research output: Contribution to journalArticle

Sunakawa, K, Ishizuka, Y, Akita, H, Iwata, S & Sato, Y 1989, 'Bacteriological and clinical evaluations of cefmenoxime in neonates and premature infants', Japanese Journal of Antibiotics, vol. 42, no. 12, pp. 2617-2626.
Sunakawa, K. ; Ishizuka, Y. ; Akita, H. ; Iwata, S. ; Sato, Y. / Bacteriological and clinical evaluations of cefmenoxime in neonates and premature infants. In: Japanese Journal of Antibiotics. 1989 ; Vol. 42, No. 12. pp. 2617-2626.
@article{882a16c8045e4ecaba9181bc3f27aab8,
title = "Bacteriological and clinical evaluations of cefmenoxime in neonates and premature infants",
abstract = "The antimicrobial activity of cefmenoxime (CMX) against B group Streptococcus was investigated. The clinical efficacy of CMX was determined in neonates and premature infants. The results are summarized below. 1. MIC's of CMX against 39 strains of B group Streptococcus obtained from the pregnant vagina were below 0.05 μg/ml. 2. CMX was given in dose of 20 mg/kg by intravenous bolus injection to 3 neonates with birth weight over 2,500 grams. Peak serum concentrations ranged from 54.0 to 199 μg/ml and the mean half/life was 1.8 hours. 3. Efficacies of CMX were good to excellent in 5 cases administered for treatment and in 4 cases for prophylaxis. As abnormal laboratory parameteres, elevation of GOT and eosinophilia were observed in each 2 cases. 4. Examinations on intestinal bacteria in 2 cases revealed that CMX gave as much influences to the flora as other third-generation cephems. 5. The vitamin K defficiency were observed in 2 out of 6 cases examined.",
author = "K. Sunakawa and Y. Ishizuka and H. Akita and S. Iwata and Y. Sato",
year = "1989",
language = "English",
volume = "42",
pages = "2617--2626",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "12",

}

TY - JOUR

T1 - Bacteriological and clinical evaluations of cefmenoxime in neonates and premature infants

AU - Sunakawa, K.

AU - Ishizuka, Y.

AU - Akita, H.

AU - Iwata, S.

AU - Sato, Y.

PY - 1989

Y1 - 1989

N2 - The antimicrobial activity of cefmenoxime (CMX) against B group Streptococcus was investigated. The clinical efficacy of CMX was determined in neonates and premature infants. The results are summarized below. 1. MIC's of CMX against 39 strains of B group Streptococcus obtained from the pregnant vagina were below 0.05 μg/ml. 2. CMX was given in dose of 20 mg/kg by intravenous bolus injection to 3 neonates with birth weight over 2,500 grams. Peak serum concentrations ranged from 54.0 to 199 μg/ml and the mean half/life was 1.8 hours. 3. Efficacies of CMX were good to excellent in 5 cases administered for treatment and in 4 cases for prophylaxis. As abnormal laboratory parameteres, elevation of GOT and eosinophilia were observed in each 2 cases. 4. Examinations on intestinal bacteria in 2 cases revealed that CMX gave as much influences to the flora as other third-generation cephems. 5. The vitamin K defficiency were observed in 2 out of 6 cases examined.

AB - The antimicrobial activity of cefmenoxime (CMX) against B group Streptococcus was investigated. The clinical efficacy of CMX was determined in neonates and premature infants. The results are summarized below. 1. MIC's of CMX against 39 strains of B group Streptococcus obtained from the pregnant vagina were below 0.05 μg/ml. 2. CMX was given in dose of 20 mg/kg by intravenous bolus injection to 3 neonates with birth weight over 2,500 grams. Peak serum concentrations ranged from 54.0 to 199 μg/ml and the mean half/life was 1.8 hours. 3. Efficacies of CMX were good to excellent in 5 cases administered for treatment and in 4 cases for prophylaxis. As abnormal laboratory parameteres, elevation of GOT and eosinophilia were observed in each 2 cases. 4. Examinations on intestinal bacteria in 2 cases revealed that CMX gave as much influences to the flora as other third-generation cephems. 5. The vitamin K defficiency were observed in 2 out of 6 cases examined.

UR - http://www.scopus.com/inward/record.url?scp=0024842919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024842919&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 2617

EP - 2626

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 12

ER -